Latest News
FDA accepts Takeda's oveporexton NDA with priority review for narcolepsy type 1
10 February 2026 - Japanese pharmaceutical company Takeda (TSE:4502) (NYSE:TAK) said on Tuesday that the the US Food and Drug Administration (FDA) has accepted its New Drug Application and granted Priority Review for oveporexton (TAK-861) for the tre...
GenSight Biologics reports first patient treated in GS010 REVISE study
10 February 2026 - Biopharmaceutical company GenSight Biologics (Euronext Paris:SIGHT) and the 15-20 National Hospital in Paris announced on Tuesday the treatment of the first patient in the REVISE dose-ranging study of GS010, also known as LUMEVOQ.T...
Eli Lilly signs definitive agreement to acquire Orna Therapeutics
10 February 2026 - US pharmaceutical company Eli Lilly and Company (NYSE:LLY) announced on Monday that it has signed a definitive agreement to acquire Orna Therapeutics Inc, a biotechnology company focused on engineering immune cells in vivo.Orna is ...
CiteAb launches new scientific image search tool and improved reagent search engine
10 February 2026 - Scientific database and research platform CiteAb announced on Monday the launch of its CiteAb Explore Platform, comprising the Reagent Search Engine and new Image Search Engine.Built on over a decade of AI-driven data collection co...
Innocan Pharma reports findings from clinical study of LPT-CBD in dogs
10 February 2026 - Canadian pharmaceutical and biotechnology company Innocan Pharma Corporation (CSE:INNO) (FSE:IP40) (OTCQB:INNPD) announced on Monday the publication of a research article titled 'Efficacy, pharmacokinetics and safety of liposo...